Consolidated Statements of Income (Loss) - USD ($) shares in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenues [Abstract]
Total revenues	$ 22,334,000	$ 59,215,000	$ 103,269,000
Operating expenses:
Cost of products	5,742,000	12,125,000	17,516,000
Research and development expenses	20,442,000	32,917,000	39,329,000
Selling, general and administrative expenses	32,405,000	30,183,000	100,359,000
Intangible asset amortization	406,000	816,000	6,619,000
Changes in fair value of contingent consideration	3,327,000	845,000	(22,731,000)
Gain on sale of Hospital Products	(45,760,000)	0	0
Impairment of intangible asset	0	0	66,087,000
Restructuring (income) costs	(43,000)	6,441,000	1,016,000
Total operating expenses	16,519,000	83,327,000	208,195,000
Operating income (loss)	5,815,000	(24,112,000)	(104,926,000)
Investment and other (expense) income, net	(832,000)	1,069,000	452,000
Interest expense	(12,994,000)	(12,483,000)	(10,622,000)
Gain from release of certain liabilities	3,364,000	0	0
Loss on deconsolidation of subsidiary	0	(2,678,000)	0
Other (expense) income - changes in fair value of contingent consideration payable	(435,000)	(378,000)	1,899,000
Loss before income taxes	(5,082,000)	(38,582,000)	(113,197,000)
Income tax benefit	(12,110,000)	(5,356,000)	(17,893,000)
Net income (loss)	$ 7,028,000	$ (33,226,000)	$ (95,304,000)
Earnings (loss) per share
Net income (loss) per share - basic (in usd per share)	$ 0.13	$ (0.89)	$ (2.55)
Net income (loss) per share - diluted (in usd per share)	$ 0.13	$ (0.89)	$ (2.55)
Weighted average number of shares outstanding
Weighted average number of shares outstanding - basic (in shares)	52,996	37,403	37,325
Weighted average number of shares outstanding - diluted (in shares)	54,941	37,403	37,325
Product sales
Revenues [Abstract]
Total revenues	$ 22,334,000	$ 59,215,000	$ 101,423,000
License revenue
Revenues [Abstract]
Total revenues	$ 0	$ 0	$ 1,846,000